for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sellas Life Sciences Group Inc

SLS.OQ

Latest Trade

0.13USD

Change

-0.00(-0.61%)

Volume

1,143,689

Today's Range

0.13

 - 

0.13

52 Week Range

0.10

 - 

2.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.13
Open
0.13
Volume
1,143,689
3M AVG Volume
625.94
Today's High
0.13
Today's Low
0.13
52 Week High
2.46
52 Week Low
0.10
Shares Out (MIL)
226.54
Market Cap (MIL)
29.68
Forward P/E
-0.94
Dividend (Yield %)
--

Latest Developments

More

Sellas Life Sciences Reports Q2 Loss Per Share $0.13

Sellas Advances Galinpepimut-S In Combination With Keytruda Program

Sellas Life Sciences Announces Pricing Of $15 Million Public Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sellas Life Sciences Group Inc

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

Industry

Biotechnology & Drugs

Contact Info

15 W 38th St Fl 10

+1.917.4384353

https://www.sellaslifesciences.com/

Executive Leadership

Angelos M. Stergiou

President, Chief Executive Officer, Director

John Thomas Burns

Principal Accounting Officer, Vice President - Finance, Controller

David A. Scheinberg

Director

Stephen F Ghighlieri

Independent Director

Robert L. Van Nostrand

Independent Director

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-70.800

2017

-10.440

2018

-2.450

2019(E)

-0.140
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.91
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-159.10
Return on Equity (TTM)
-74.67

Latest News

BRIEF-Sellas Life Sciences Files For Offering Of Up To $30 Mln

* SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING Source text: (https://bit.ly/2klt2uI) Further company coverage:

BRIEF-Sellas Life Sciences Group Files Preliminary Prospectus Related To Offering Of 3.2 Mln Shares Of Common Stock

* SELLAS LIFE SCIENCES GROUP FILES PRELIMINARY PROSPECTUS RELATED TO OFFERING OF 3.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS -SEC FILING Source: (https://bit.ly/2I5iC0q) Further company coverage:

BRIEF-Sellas Life Sciences Receives FDA Orphan Drug Designation For Galinpepimut-S For Treatment Of Multiple Myeloma

* SELLAS LIFE SCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GALINPEPIMUT-S (GPS) FOR TREATMENT OF MULTIPLE MYELOMA (MM) Source text for Eikon: Further company coverage:

BRIEF-Sellas Life Sciences Ceases Gregory Torre's Employment As Chief Regulatory Officer

* SELLAS LIFE SCIENCES GROUP- ON APRIL 19, CO AND GREGORY TORRE, AGREED THAT HIS EMPLOYMENT AS CHIEF REGULATORY OFFICER WOULD CEASE - SEC FILING

BRIEF-Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer

* SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER

BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin

* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS

BRIEF-Sellas Life Sciences Announces $10.7 Mln Private Placement

* SELLAS LIFE SCIENCES ANNOUNCES $10,700,000 PRIVATE PLACEMENT

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up